Study of the Mechanism of Action of Blarcamesine (ANAVEX®2-73): Whole Blood Transcriptomics Analysis (RNAseq)
Identifies Treatment Impact on Compensatory Pathways by Restoring Key Neurodegenerative Pathways Functionality,
including Alzheimer’s and Parkinson’s Disease Pathways.
C. Williams (1), M. Kindermans (1) , F. Parmentier (1), F. Goodsaid (1), E. Hammond (2), C. Missling (2), M. Afshar (1)
(1)-Tersan Pharmaceuticals Ltd, Paris, France, (2)-Anavex Life Sciences, New York, NY, USA
